ATE439363T1 - Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides - Google Patents

Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides

Info

Publication number
ATE439363T1
ATE439363T1 AT02784979T AT02784979T ATE439363T1 AT E439363 T1 ATE439363 T1 AT E439363T1 AT 02784979 T AT02784979 T AT 02784979T AT 02784979 T AT02784979 T AT 02784979T AT E439363 T1 ATE439363 T1 AT E439363T1
Authority
AT
Austria
Prior art keywords
imidazo
formula
sulfonamides
thiadiazole
thiadiazole sulfonamides
Prior art date
Application number
AT02784979T
Other languages
English (en)
Inventor
James Jaquith
Gerald Villeneuve
Alain Boudreault
Stephen Morris
Jon Durkin
John Gillard
Kimberly Hewitt
Nicholas Marsh
Original Assignee
Aegera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegera Therapeutics Inc filed Critical Aegera Therapeutics Inc
Application granted granted Critical
Publication of ATE439363T1 publication Critical patent/ATE439363T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
AT02784979T 2001-12-14 2002-12-16 Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides ATE439363T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002364985A CA2364985A1 (en) 2001-12-14 2001-12-14 Imidazo(2,1-b)thiadiazole sulfonamides
PCT/CA2002/001942 WO2003051890A1 (en) 2001-12-14 2002-12-16 Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides

Publications (1)

Publication Number Publication Date
ATE439363T1 true ATE439363T1 (de) 2009-08-15

Family

ID=4170835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02784979T ATE439363T1 (de) 2001-12-14 2002-12-16 Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides

Country Status (11)

Country Link
US (8) US7230019B2 (de)
EP (1) EP1463735B1 (de)
JP (2) JP2005519882A (de)
AT (1) ATE439363T1 (de)
AU (1) AU2002350333B2 (de)
CA (1) CA2364985A1 (de)
DE (1) DE60233350D1 (de)
DK (1) DK1463735T3 (de)
ES (1) ES2329882T3 (de)
PT (1) PT1463735E (de)
WO (1) WO2003051890A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364985A1 (en) * 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
WO2004111060A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics Inc. IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES
EP1636242A1 (de) * 2003-06-13 2006-03-22 Aegera Therapeutics Inc. Acylierte und nicht-acylierte imidazo(2,1-b)-1,3,4-thiadiazol-2-sulfonamide und deren verwendung
WO2007034278A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Fused imidazole derivatives as c3a receptor antagonists
US20090179638A1 (en) * 2006-02-01 2009-07-16 Aegera Therapeutics Inc. Assay for identifying inhibitors of neuronal apoptotic pathways
AU2008209320B2 (en) * 2007-01-25 2013-05-30 NAIA Metabolic, Inc. Insulin sensitisers and methods of treatment
EP2193133B1 (de) * 2007-09-27 2015-08-19 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Imidazolothiadiazole zur verwendung als proteinkinaseinhibitoren
ES2548571T3 (es) 2009-04-02 2015-10-19 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Derivados de imidazo[2,1-b][1,3,4]tiadiazol
US8771324B2 (en) 2011-05-27 2014-07-08 Globus Medical, Inc. Securing fasteners
EP2855489B1 (de) 2012-04-26 2017-01-04 Bristol-Myers Squibb Company Imidazothiadiazol- und imidazopyridazinderivate als proteaseaktivierte rezeptor 4 (par4)-inhibitoren zur behandlung von thrombozytenaggregation
EA201491967A1 (ru) 2012-04-26 2015-03-31 Бристол-Майерс Сквибб Компани Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов
SMT201700457T1 (it) 2012-04-26 2017-11-15 Bristol Myers Squibb Co DERlVATI IMIDAZOTIADIAZOLICI E IMIDAZOPIRAZINICI COME INIBITORI DEL RECETTORE ATTIVATO DA PROTEASI 4 (PAR4) PER IL TRATTAMENTO DELL'AGGREGAZIONE PIASTRINICA
EP3053908B1 (de) * 2013-09-30 2018-12-19 FUJIFILM Corporation Verfahren zur herstellung einer alpha-halogenoacetophenonverbindung und alpha-bromoacetophenonverbindung
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
WO2017184520A1 (en) * 2016-04-18 2017-10-26 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
KR20210052435A (ko) 2018-08-30 2021-05-10 니혼 메디피직스 가부시키가이샤 방사성 이미다조티아디아졸 유도체 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US52514A (en) * 1866-02-13 Stove-pipe damper
GB1464259A (en) * 1975-10-03 1977-02-09 Pfizer Ltd Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
WO1999062880A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
CA2364985A1 (en) * 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
CA2379375A1 (en) * 2002-03-28 2003-09-28 Apotex Inc. Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases

Also Published As

Publication number Publication date
US7714003B2 (en) 2010-05-11
US20070238768A1 (en) 2007-10-11
US7772260B2 (en) 2010-08-10
PT1463735E (pt) 2009-10-15
JP2010106030A (ja) 2010-05-13
US7741349B2 (en) 2010-06-22
US20070088059A1 (en) 2007-04-19
WO2003051890A1 (en) 2003-06-26
US7230019B2 (en) 2007-06-12
DE60233350D1 (de) 2009-09-24
JP2005519882A (ja) 2005-07-07
DK1463735T3 (da) 2009-12-14
ES2329882T3 (es) 2009-12-02
US20070265319A1 (en) 2007-11-15
AU2002350333A1 (en) 2003-06-30
US20090042953A1 (en) 2009-02-12
AU2002350333B2 (en) 2008-08-21
US7700635B2 (en) 2010-04-20
US20070238766A1 (en) 2007-10-11
US20050069492A1 (en) 2005-03-31
US20070021416A1 (en) 2007-01-25
CA2364985A1 (en) 2003-06-14
EP1463735B1 (de) 2009-08-12
US20070021476A1 (en) 2007-01-25
EP1463735A1 (de) 2004-10-06

Similar Documents

Publication Publication Date Title
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
SI1425277T1 (sl) Seäśninske spojine, aktivne kot vaniloidni receptorski antagonisti za zdravljenje boleäśine
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
GB0225474D0 (en) Therapeutic agents
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
MA27933A1 (fr) Inhibiteurs de l'activite de akt
GB0111186D0 (en) Novel compounds
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
GB0223038D0 (en) Therapeutic compounds
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
TW200505904A (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1463735

Country of ref document: EP

REN Ceased due to non-payment of the annual fee